Contending for CD47 throne, Arch Oncology scores $50M as it ramps up PhI studies
Arch Oncology, one of the older startups in a crop of immuno-oncology players chasing after the CD47 target, has bagged $50 million to fuel a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.